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Antisense oligonucleotides (AONs) are being developed 
as RNA therapeutic molecules for Duchenne muscular 
dystrophy. For oligonucleotides with the 2′-O-methyl-
phosphorothioate (2OMePS) RNA chemistry, proof of 
concept has been obtained in patient-specific muscle 
cell cultures, the mouse and dog disease models, and 
recently by local administration in Duchenne patients. 
To further explore the pharmacokinetic (PK)/pharma-
codynamic  (PD)  properties  of  this  chemical  class  of 
oligonucleotides, we performed a series of preclinical 
studies in mice. The results demonstrate that the   levels 
of  oligonucleotides  in  dystrophin-deficient  muscle 
fibers are much higher than in healthy fibers, leading 
to higher exon-skipping levels. Oligonucleotide levels 
and half-life differed for specific muscle groups, with 
heart  muscle  showing  the  lowest  levels  but  longest 
half-life  (~46  days).  Intravenous  (i.v.),  subcutaneous 
(s.c.), and intraperitoneal (i.p.) delivery methods were 
directly  compared.  For  each  method,  exon-skipping 
and  novel  dystrophin  expression  were  observed  in 
all muscles, including arrector pili smooth muscle in 
skin biopsies. After i.v. administration, the oligonucle-
otide  peak  levels  in  plasma,  liver,  and  kidney  were 
higher than after s.c. or i.p. injections. However, as 
the bioavailability was similar, and the levels of oligo-
nucleotide,  exon-skipping,  and  dystrophin  steadily 
accumulated  overtime  after  s.c.  administration,  we 
selected this patient-convenient delivery method for 
future clinical study protocols.
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IntroductIon
The  severe  and  progressive  deterioration  of  muscle  fibers  in 
Duchenne muscular dystrophy (DMD) is caused by the deficiency 
of dystrophin, a protein that is essential for the integrity of muscle 
fiber membranes.1 In DMD patients, mutations in the DMD gene, 
mostly deletions of one or more exons (~72%),2 disrupt the open 
reading frame of the transcript and prematurely abort the syn-
thesis of the dystrophin protein.3 Patients with Becker muscular 
dystrophy show intermediate-to-milder phenotypes with mostly 
longer-to-normal life expectancies when compared with DMD 
patients. Here, the mutations in the DMD gene maintain the open 
reading frame and result in an internally truncated but semifunc-
tional dystrophin.3,4
Antisense oligonucleotides (AONs) are innovative synthetic 
drugs currently being developed for the treatment of DMD.5 Based 
on  specific  chemical  modifications  their  mechanism  of  action 
here is not RNase H-mediated cleavage of target RNA, but instead 
induction of specific exon-skipping by disturbing exon inclusion 
signals during pre-mRNA splicing. Mutation-specifically targeted 
skipping of 1 or more exons in DMD patients allows restoration of 
the mutated open reading frame, introduction of novel dystrophin 
synthesis, and conversion of a severe DMD into a (much) milder 
Becker muscular dystrophy phenotype.5
Two  different  AON  chemistries  are  currently  being  stud-
ied  extensively  toward  clinical  application:  2′-O-methyl-
phosphorothioate  (2OMePS)  RNA  and  phosphorodiamidate 
morpholino  oligomer  (PMO).6  Both  have  been  shown  to  be 
effective in inducing exon-skipping and dystrophin restoration 
in cultured muscle cells from a series of DMD patients with dif-
ferent mutations, in the mdx and transgenic human DMD mouse 
models, and in the DMD dog model.7–15 Peptide conjugated PMOs 
were more efficient than their unconjugated counterpart, espe-
cially in heart.16,17
Although PMO targeting mouse exon 23 appears to be more 
effective  than  2OMePS,  this  difference  was  not  observed  for 
human target exons.6 AONs of both chemistries targeting exon 51 
were  equally  efficient  in  human  proof-of-concept  studies.18 
The first trial involved PRO051 (2OMePS).19 Four Dutch DMD 
patients received an intramuscular (i.m.) injection of a single dose 
(0.8 mg). The compound was safe, well-tolerated, and effective in 
specifically inducing exon 51 skipping and dystrophin restoration 
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(up to 35%) in the majority of muscle fibers (up to 97%) in the 
treated area. Recently, i.m. injection of 0.9 mg AVI-4658 (PMO) 
in  five  DMD  patients  also  demonstrated  to  be  well-tolerated, 
inducing dystrophin levels of up to 32% in 79% of the fibers in the 
treated area.20
Although both studies confirm proof of concept, they only 
resulted in local dystrophin synthesis. To allow body-wide pro-
duction,  systemic  AON  delivery  is  required.  Intravenous  (i.v.) 
delivery of a mouse exon 23–specific 2OMePS AON (23AON) 
in mdx mice previously showed whole-body dystrophin, albeit at 
variable levels: minimal in heart, high in gastrocnemius muscle.21 
Interestingly, early signs for effective accumulation were observed; 
after three injections of the 23AON the levels of dystrophin that 
accumulated  were  comparable  with  levels  observed  after  one 
injection.
For future clinical studies on systemic delivery of AONs, more 
extensive  pharmacokinetic  (PK)  and  pharmacodynamic  (PD) 
studies are required to determine the optimal dose, regimen, route 
of  administration,  and  accordingly  biodistribution,  clearance, 
muscle specific uptake, and AON half-life. Here, we describe a 
series of PK/PD experiments in mdx mice as part of the preclini-
cal development of 2OMePS AONs for DMD.
results
enhanced levels of 2oMePs rnA Aons  
in dystrophic muscle
PK data on AONs are fundamental for the optimization of dose 
and regimen for systemic treatment of DMD patients, especially 
because this treatment will be chronic. Here, we applied a quanti-
tative and sequence-specific hybridization ligation assay to study 
the biodistribution of 2OMePS RNA AONs upon systemic deliv-
ery.6 First, we confirmed a previously observed phenomenon of 
enhanced exon-skipping efficiencies in dystrophic muscle when 
compared to healthy muscle.11 Both wild-type and mdx mice (n = 
3, similar age) received a single i.v. 50 mg/kg dose of a mouse-spe-
cific 2OMePS RNA AON, inducing exon 23 skipping [M23D(+02–
18)].21,22 At 48 hours postinjection, the gastrocnemius and triceps 
muscles showed four and eight times higher 23AON levels (up 
to  10 μg/g),  respectively,  in  mdx  mice  than  in  wild-type  mice 
(Figure 1a). The 23AON levels in heart were markedly lower but 
still 2.5 times higher in mdx than in wild-type mice. This differ-
ential uptake was not observed in kidney and liver, which showed 
high (up to 100 μg/g) but equal levels of 23AON in both mouse 
groups. These results confirm that there is an enhanced absorp-
tion of 23AON from the blood circulation, probably due to the 
myogenic degeneration and regeneration processes in the mdx 
mice, associated with a higher permeability of the myofiber mem-
branes and/or vascular system.
In a related experiment, the levels of exon 23 skipping in wild-
type versus mdx mice (n = 3, similar age) were monitored over a 
period of 2 weeks after two 20-μg i.m. injections (24-hour interval) 
of the 23AON (Figure 1b). In wild-type mice, the levels were very 
low, up to 2% at 4 days after treatment. Given the lower 23AON 
levels in healthy muscle, this was anticipated. In contrast, in the 
mdx mice exon 23 skipping levels were 4–20 times higher than 
in wild-type mice, and increased over time up to 20% at 10 days 
postinjection. This PD pattern suggests that 2OMePS RNA AONs 
are stable within muscle fibers, and that the levels of   in-frame tran-
script after exon 23 skipping can therefore accumulate over time.
Half-life of 2oMePs rnA Aons in mdx tissue
To study the stability (half-life) of 2OMePS RNA AONs in mdx 
muscle tissue, a series of mdx mice were given three i.v. injections 
of 100 mg/kg 23AON in 1 week (every other day). At 2, 4, 7, and 
14 days after the last injection, two mice were killed for analysis. 
AON levels were assessed in the gastrocnemius, triceps, and quad-
riceps muscles, heart, kidney, and liver (Figure 2a). The uptake of 
the compound by the kidney and liver was higher (up to 10 times) 
than in skeletal muscle. However, the relative clearance was also 
markedly faster. The levels of AON in the different skeletal mus-
cle groups were similar (36–45 μg/g) at day 2 and persisted for at 
least 14 days at levels of ~40% (gastrocnemius and quadriceps) and 
78% (triceps). The lowest levels of AON were observed in the heart 
(11 μg/g), but 80% of this was still detected after 14 days. Based on 
these data, the half-life of the 2OMePS 23AON was determined 
for different tissues (Figure 2b) and was found to be similar in the 
gastrocnemius and quadriceps muscles (~10 days), but markedly 
higher in the triceps muscle (~33 days). This may have been due 
to a lower extent of degeneration and regeneration in the higher 
extremities, and/or to a differential type I/II fiber content. The same 
phenomenon may explain the markedly longer half-life of the AON 
in cardiac muscle tissue (~46 days). This observation is encouraging 
because it implies that the relatively low 2OMePS RNA AON levels 
in heart may be compensated overtime by a prolonged persistence 
and thus accumulation of AON in repeated-dosing studies.
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Figure 1  enhanced levels of 2oMePs rnA Aons in dystrophic mus-
cle. (a) Comparison of AON levels in skeletal muscles (gastro  cnemius 
and triceps muscle), heart, kidney, and liver from wild-type (WT) versus 
mdx mice (n = 3), after a single intravenous (i.v.) injection of 50 mg/
kg mouse exon 23–specific 2′-O-methyl-phosphorothioate antisense oli-
gonucleotide (23AON). (b) Comparison of exon 23 skipping levels in 
gastrocnemius muscles from series of WT versus mdx mice (n = 3), at dif-
ferent time points (up to 14 days) after 2 intramuscular (i.m.) injections 
of 20 μg 23AON (with 24-hour interval).1212  www.moleculartherapy.org  vol. 18 no. 6 june 2010     
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the effect of different routes of administration 
on 2oMePs rnA Aon pharmacokinetics
The route of administration affects the PK characteristics of thera-
peutic molecules. We therefore evaluated the PK/PD profiles of 
the 23AON after i.v., intraperitoneal (i.p.), subcutaneous (s.c.), 
and i.m. injections in mdx mice (all at age ~3 weeks) from different 
independent experiments. First, the effect of the different routes of 
administration on AON plasma levels and clearance was assessed 
(Figure 3a). After a single i.v. injection of 50 mg/kg (~1 mg/ani-
mal) 23AON, the levels in plasma 5 minutes postinjection were 
high (78 μg/ml), with almost complete clearance after 90 minutes. 
This pattern was similar in wild-type mice. I.p. and s.c. injections 
of half this dose (25 mg/kg) in mdx mice resulted in twofold lower 
plasma levels (43 and 36 μg/ml, respectively), and a slower clear-
ance than i.v. injection. Remarkably, we observed relatively high 
and sustained AON plasma levels (50–60 μg/ml) after a single i.m. 
injection of 12.5 mg/kg (0.25 mg/animal) of 23AON. These results 
suggest that there is a delayed and continuing release of AON 
from bodily tissue to the blood circulation, which is especially sig-
nificant in mdx muscle tissue (still at 39 μg/  ml after 90 minutes).
To further study the extent of the whole-body therapeutic 
effects after AON treatment and to enhance any potential PK/
PD differences between the delivery methods studied, we then 
compared the different routes of administration at a high dose of 
250 mg/kg 23AON. Sets of three mdx mice received 250 mg/  kg 
of 23AON five times in 1 week by either i.v., i.p., or s.c. injec-
tions. They were killed at 3 days after the last injection. The rela-
tive levels of AON in different muscle groups, being on average 
5–10 times lower than in kidney and liver, did vary slightly with 
the different routes of administration: ~1.3 times higher lev-
els after i.v. versus i.p. or s.c. administration (Figure 3b). The 
effect of delivery method on the kidney and the liver levels was 
much stronger. I.v. injections resulted in the highest acute levels 
of AON in kidney (725 μg/g) and liver (650 μg/g) when com-
pared with the i.p. (345 and 235 μg/g, respectively) and s.c. (355 
and 275 μg/g, respectively) injections. Therefore, at this dose 
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Figure 2  Half-life of 2oMePs rnA Aons in mdx tissue. (a) Antisense 
oligonucleotide (AON) tissue levels in gastrocnemius (G), triceps (T), 
quadriceps (Q), heart (H), kidney (K), and liver (L) of mdx mice after 
three intravenous injections of 100 mg/kg mouse exon 23–specific 2′-O-
methyl-phosphorothioate AON (23AON), monitored from 2 to 14 days 
postinjection. (b) The half-life of the 23AON in different muscle groups 
and organs.
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and regimen, i.v. injections may be less tolerable. I.p. and s.c. 
injections clearly showed a less acute PK pattern in kidney and 
liver.
The typical PK profile as per route of administration directly 
correlated with the PD effects in muscle. The levels of exon 23 
skipping in a series of skeletal muscle groups, the heart, and dia-
phragm, isolated from the same set of treated mdx mice dem-
onstrated  that  the  i.v.  route  of  administration  did  allow  the 
highest levels of exon-skipping (up to 43% of total transcripts in 
the quadriceps and 4% in heart; Figure 3c). With the i.p. and 
s.c. routes the percentages of exon 23 skipping were typically 
lower: 40–80% (s.c.) and 30–70% (i.p.) of those obtained after 
i.v. administration, depending on the specific muscle group ana-
lyzed. Independent of the administration route, the exon 23 skip-
ping levels varied between the specific muscle groups analyzed, 
with the highest levels in the quadriceps and gastrocnemius mus-
cles. This correlates with the higher AON levels in these muscles 
when compared, for instance, to the triceps muscle (Figure 2a). 
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Differences in muscle group–specific response to 23AON were 
also observed on protein levels. Western blot analysis of total pro-
tein extracts from the quadriceps, triceps, and heart muscles of 
the mice that were treated by i.v. injection demonstrated gener-
ally higher dystrophin levels in the quadriceps than the triceps 
muscles (Figure 3d). Relatively high levels of dystrophin expres-
sion were observed in the heart samples. This may at least partly 
be explained by the longer half-life of the 23AON in the heart 
(Figure 2b).
optimization of PK and Pd profiles of 2oMePs rnA 
Aons in mdx mice after s.c. administration
Given the lower acute 23AON plasma levels and lower liver and 
kidney load after s.c. administration, we further focused on s.c. 
dosing and regimen. Groups of mdx mice received s.c. doses of 25, 
50, or 100 mg/kg of 23AON twice weekly, over a period of 4 or 8 
weeks. Saline-treated mice were used as a control group. No behav-
ioral differences were observed between AON-treated and saline-
treated mice throughout the treatment period. Following these 
treatments,  different  serum  parameters  (glutamic-  oxalocetic 
transaminase, ureas, hemoglobin, creatine, alkaline phosphatase, 
and glutamic-pyruvic transaminase) were assessed and did not 
indicate toxic effects on liver and kidney (data not shown). In 
addition, the weight of liver, kidney, and spleen did not differ 
between treated and nontreated animals.
AON  pharmacokinetics  and  overall  muscle  integrity  and 
function were assessed during and after treatment. First, for each 
dose, 23AON plasma levels were assessed over time (Figure 4a). 
Increasing doses resulted in increasing plasma peak levels, but per 
dose, these peak levels did not increase over time; similar levels 
were obtained in either weeks 1, 3, and 7. The 23AON was rapidly 
cleared from the blood circulation, which may reflect a fast and 
significant absorption by the dystrophic muscle tissue. In contrast 
to the plasma peak levels, the plasma trough levels showed a steady 
accumulation over time and at increased levels (i.e., total plasma 
exposure) with increased dose. These levels most likely correlated 
to the muscle tissue exposure and to the PD response therein. In 
fact, the levels of 23AON in the tibialis anterior muscle demon-
strated accumulation of the compound over time, and increased 
per subsequent higher dose group (Figure 4b, left panel). These 
dose-dependent PK profiles directly correlated with the levels of 
exon 23 skipping and dystrophin expression in the same tibialis 
anterior muscle (Figure 4b, middle and right panels). Tissue   levels 
of ~4 μg/g were sufficient to induce low levels of exon-skipping. 
By contrast, for the highest dose (100 mg/kg), the exon 23 skip-
ping level was up to 11% after 8 weeks, with associated dystrophin 
levels up to 6% of that in normal muscle tissue (Figure 4c).
Plasma  creatine  kinase  (CK)  levels  were  also  determined 
weekly during treatment (Figure 4d). CK is a muscle enzyme 
that leaks into the bloodstream when muscle fibers are damaged 
and is therefore considered an early biomarker for muscle integ-
rity. In untreated mdx mice, the CK levels vary but are typically 
elevated to 1,500–3,000 U/l. For the mdx mice in the 100 mg/kg 
group, the CK levels were found to be significantly lower over-
time (P value <1 × 10−5) than those in the saline-treated mice, 
whereas they were comparable before treatment. The seemingly 
increased muscle fiber integrity in the mice in this high-dose 
group probably contributed to the improved muscle performance 
as observed by Rotarod analysis over time (Figure 4e). Both the 
saline and the 100 mg/kg 23AON-treated mice showed increased 
running times during the first 2 weeks (learning curve), but then 
running  times  decreased  after  2  weeks.  However,  the  decline 
for the 23AON-treated mice was much more gradual than for 
saline-treated mice. In addition, the plateau level of treated mice 
was higher (300 seconds versus ~170 seconds). This difference 
between the untreated and treated groups was significant over 
time (P value <1 × 10−4).
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Figure 5  dystrophin restoration in skin arrector pili. (a) Dystrophin 
and desmin immunofluorescence staining of arrector pili smooth mus-
cle in skin biopsies from neck scruff (NS), anterior leg (AL) and dorsal 
tail regions (DT) from treated (s.c., 100 mg/kg) and untreated (saline) 
mdx mice versus wild-type mice. Desmin (green) colocalizes with dys-
trophin (red) and is expressed in all animals. No dystrophin labeling 
was detected in untreated animals, while dystrophin is expressed in all 
treated and wild-type animals. Bar = 400 μm. (b) Dystrophin immuno-
fluorescence staining of panniculus carnosus in skin biopsy from the DT 
in wild-type (left panel), untreated (middle panel), and treated (right 
panel) mice. Dystrophin labeling is intense and continuous at the sarco-
lemma of muscle fibers of panniculus carnosus of wild-type skin biopsy 
and absent in mdx mice. In mdx mice treated with AONs, dystrophin 
labeling is detected at the sarcolemma of muscle fibers with an almost 
continuous pattern. All samples were photographed at the same expo-
sition time and the images were not differently manipulated. Nuclei are 
stained with DAPI. Bar = 200 μm.Molecular Therapy  vol. 18 no. 6 june 2010  1215
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dystrophin restoration in skin arrector pilli
For six mice treated with 100 mg/kg 23AON s.c., dystrophin res-
toration was monitored in smooth muscle of the skin (arrector 
pili muscle). It was previously demonstrated that skin biopsies 
may be used for the diagnosis of DMD or Becker muscular dys-
trophy on the basis of immunostaining of dystrophin in arrector 
pili muscles.23,24 In addition, we recently demonstrated dystrophin 
restoration  after  treatment  of  2OMePS  AONs  complexed  with 
nanoparticles in the mdx mouse model.25 Indeed, in the three 
mice receiving 8 weeks of 23AON treatment, clear dystrophin sig-
nals were observed in the arrector pili muscles all over the skin 
(anterior leg, dorsal tail region, neck scuff region; Figure 5a). 
Dystrophin restoration was also clearly visible in the pannicu-
lus carnosus, a skeletal muscle layer of the skin (Figure 5b). The 
immunostaining patterns obtained were similar to those observed 
in healthy wild-type mice, whereas no dystrophin signals were 
observed in the saline-treated mice.
dIscussIon
Two different AON chemistries are most advanced in preclini-
cal and clinical development for DMD: 2OMePS RNA and PMO. 
Although their modes of action are identical, 2OMePS and PMO 
compounds have significantly different chemical structures and 
associated characteristics and, even when targeting an identical 
sequence, require independent toxicity and PK versus PD stud-
ies. Before clinical studies applying systemic delivery of 2OMePS 
compounds, we performed a large series of preclinical PK/PD 
studies in the mdx mouse model with a mouse exon 23–specific 
compound of the same chemistry. The effects of dose, regimen, 
treatment period, and route of administration on biodistribution, 
specific muscle tissue availability, and molecular response were 
assessed.
For  the  biodistribution  studies  a  quantitative  and  AON 
sequence-specific  hybridization  ligation  assay  was  applied.  It 
allowed quantification of AON levels in plasma but also in dif-
ferent tissues and organs, albeit without discrimination between 
internalized and still-circulating molecules.6 One of our first obser-
vations was that, in mdx mouse muscle, higher levels of 23AON 
were present than in healthy mouse muscle. As this was corre-
lated with similarly higher levels of exon-skipping, these results 
confirm  the  increased  membrane  permeability  of  dystrophin-
deficient and regenerating muscle fibers.26 Therefore, in contrast 
to many other disease applications, 2OMePS AONs for DMD do 
not need targeting or uptake-enhancing moieties or formulations 
to reach sufficient therapeutic levels. This also indicates that stud-
ies on 2OMePS AONs in healthy animals or human volunteers 
are of limited use because the AON absorption by healthy muscle 
fibers is low and the biodistribution and related possible toxic-
ity profiles are quite different from that in DMD patients. It has 
been postulated that AONs diffuse into the muscle fibers through 
the same “holes” from which CK leaks out.26 As elevated CK lev-
els are present in Becker patients as well, it is anticipated that the 
enhanced absorption of AONs will continue even upon restora-
tion of the Becker-like dystrophin. This would also explain why 
exon-skipping levels in heart were lower. Although dystrophin-
negative heart muscle is affected, it does not have the “holes” that 
help improved AON absorption in skeletal muscle fibers.
Other important PK observations were that not only the levels 
of AONs but also the half-life of 23AON varied between specific 
mdx muscle groups. Both parameters determine the final molecu-
lar response for different muscle groups. In the heart for instance, 
the initial levels were 3–5 times lower than in skeletal muscle, but 
based on the 3–5 times longer half-life the dystrophin levels may 
eventually be similar to those in skeletal muscle. A   differential 
muscle group response, likely caused by specific muscle group 
function,  muscle  structure,  and/or  fiber  type  content,  should 
be taken into account when designing systemic clinical trials in 
which  specific  muscle  groups  are  studied  for  clinical  outcome 
measures and molecular effect levels. It remains to be determined 
whether such differences may become more prominent or level 
out in DMD patients after long-term treatment.
For DMD patients requiring chronic administration of AONs, 
an s.c. route of administration is clearly preferred. Our studies in 
mdx mice show that the AON bioavailability for muscle tissue is 
quite similar after i.v. or s.c. delivery. Whereas the levels of exon-
skipping were typically higher in most muscle groups after i.v. 
administration, this was also accompanied by equally higher peak 
levels of AON in plasma, kidney, and liver. Therefore, the s.c. route 
was preferred to limit the risk of organ toxicity. In a follow-up 
study, we thus further studied dose and treatment duration with 
s.c. injections. Groups of mdx mice received increasing doses (25, 
50, and 100 mg/kg, twice weekly) and either for 4 or 8 weeks. We 
clearly observed increasing levels of AON in muscle with increas-
ing doses and also accumulation of AON over time, which was 
directly  correlated  with  exon-skipping,  dystrophin  levels,  and 
improved muscle fiber integrity and function. After 8 weeks of 
treatment, even at the highest dose, steady-state levels were not 
yet reached. Further studies in mdx mice are necessary to deter-
mine when steady-state levels are reached using different doses, 
and what levels of dystrophin (compared to healthy control) are 
then achieved in the different muscle groups. Based on the obser-
vation  that  both  compound  and  dystrophin  levels  accumulate 
over time, multiple low doses may be preferred over fewer high 
doses to minimize the risk of toxic effects. A similar hypothesis 
was recently described for PMO in mdx mice.27
Finally, we show here that skin biopsies can be used to detect 
dystrophin restoration in arrector pili smooth muscle after AON 
treatment. This is an important finding that may have high value 
in future clinical studies. It is a markedly less invasive method 
than muscle biopsy sampling (relevant for discussions with medi-
cal ethics committees) and may even allow multiple biopsies over 
time or at different locations to monitor treatment effects.
In conclusion, results from these PK/PD studies on 2OMePS 
in the mdx mouse model have allowed the generation of various 
PK simulation models and facilitated rational design of toxicity 
studies as well as a phase I/IIa study on PRO051. We show that 
2OMePS AONs are taken up at high levels by dystrophic muscle, 
that 2OMePS AONs are stable and have a favorable PK profile and 
that they can easily be delivered by s.c. injections.
MAterIAls And MetHods
Administration  of  2OMePS  AONs  in  mdx  mice.  Mdx (C57Bl/10ScSn-
mdx/J) and wild-type (C57Bl/6) mice were obtained from Charles River 
Laboratories (Maastricht, the Netherlands). All experiments were authorized 1216  www.moleculartherapy.org  vol. 18 no. 6 june 2010     
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by the animal experimental commission of the Leiden University Medical 
Center (project no. 00095, 03027, 06061, and 07151). The AON applied 
in these experiments was a mouse-specific 2OMePS RNA (a full-length 
phosphorothioate backbone and 2′-O-methyl modified ribose molecules) 
inducing exon 23 skipping [M23D(+02–18)].21 The AON was administered 
in saline at doses of 12.5, 25, 50, 100, or 250 mg/kg by either i.m., i.v., i.p., or 
s.c. injections (see Supplementary Table S1). For the i.m. injections, mice 
were anesthetized by i.p. injection of a 1:1 (vol/vol) Hypnorm/Dormicum 
solution  (Janssen  Pharmaceutica,  Geel,  Belgium/Roche  Diagnostics, 
Almere, the Netherlands). In all experiments, groups of at least three mice 
were used, typically around 3–4 weeks of age. For plasma PK analysis, a 
series of blood samples were collected directly after dosing, from 0.5 to 90 
minutes. Mice were killed at different time points after the last injection 
(2–14 days). Different skeletal muscle groups, heart, kidney, and liver were 
isolated and frozen in liquid nitrogen-cooled 2-methylbutane.
AON hybridization ligation assay. The assay for measuring the concen-
tration of 2OMePS oligoribonucleotide 23AON in plasma and tissue sam-
ples is based on a hybridization ligation assay as published by Yu et al.28 A 
template probe (5′-gaatagacgaggtaagccgaggtttggcc-biotin-3′, 29-mer DNA 
phosphate  oligonucleotide)  and  a  ligation  probe  (5′-P-cgtctattc-DIG-3′, 
9-mer DNA phosphate oligonucleotide) were used. The sample was incu-
bated with the template probe (50 nmol/l) at 37 °C for 1 hour, and the 
hybridized samples were transferred to streptavidin-coated 96-well plates. 
Subsequently, the digoxigenin-labeled ligation probe (2 nmol/l) was added. 
Detection was performed with anti-DIG-POD (1:4,000; Roche Diagnostics), 
3,3′,5,5′-tetramethylbenzidine substrate (Sigma Aldrich, Zwijndrecht, the 
Netherlands), and stop solution (Sigma Aldrich). Absorption at 450 nm was 
measured in a BioTek Synergy HT plate reader (Beun de Ronde, Abcoude, 
the  Netherlands).  The  plasma  samples  were  first  diluted  tenfold  with 
phosphate-buffered saline (PBS) (Invitrogen, Breda, the Netherlands) and 
subsequent dilutions were done in 1% control mouse plasma (Innovative 
Research, NIBIO, Amsterdam, the Netherlands) in PBS. The absorption was 
read against a calibration curve of 23AON prepared in 10% control mouse 
plasma in PBS. The tissue samples were homogenized to a concentration of 
60 mg/ml in protK buffer (100 mmol/l Tris–HCl, pH 8.5, 200 mmol/l NaCl, 
5 mmol/l EDTA, 0.2% sodium   dodecyl sulfate) containing 2 mg/ml of pro-
teinase K (Invitrogen), followed by incubation for 2 hours (liver) or 4 hours 
(kidney, heart, and skeletal muscle) rotating at 55 °C in a hybridization 
oven. Next, the samples were centrifuged for 15 minutes at maximum speed 
and the supernatant was used in the assay. For liver and kidney samples, all 
dilutions (at least 200-fold) were done in PBS and the absorption was read 
against a calibration curve in control liver or kidney diluted in PBS. Heart 
and muscle samples were first diluted 60-fold in PBS, subsequent dilutions 
and the calibration curves were done in 60-fold control heart or muscle in 
PBS.
Reverse transcription-PCR analysis. Muscle samples were homogenized in 
the RNA-Bee solution (Campro Scientific, Veenendaal, the Netherlands) 
using a MagNaLyser (Roche Diagnostics) and MagNaLyser green beads 
(Roche Diagnostics). Total RNA was isolated and purified according to 
the manufacturer’s instructions. For complementary DNA synthesis with 
Transcriptor  Reverse  Transcriptase  polymerase  (Roche  Diagnostics), 
400 ng of RNA was used in a 20 μl reaction at 60 °C for 30 minutes and 
reverse primed with an exon 25 mouse-specific primer. First, PCRs were 
performed with outer primers in exons 21 and 26, for 20 cycles of 94 °C (40 
seconds), 60 °C (40 seconds), and 72 °C (60 seconds). One microliter of this 
reaction mixture (diluted 1:10) was then re-amplified using nested primers 
in exons 22 and 24 with 32 cycles of 94 °C (40 seconds), 60 °C (40 seconds), 
and 72 °C (60 seconds). PCR products were analyzed on 2% agarose gels. 
Skipping efficiencies were semiquantitatively determined as percentages 
of the total (skip and unskipped) amount by quantification of PCR prod-
ucts using the DNA 1000 LabChip Kit and the Agilent 2100 bioanalyzer 
(Agilent Technologies, Amstelveen, the Netherlands).
Western  blot  analysis. Western blotting was performed as described.29 
Briefly, muscles were homogenized to a concentration of 25 mg/ml in treat-
ment buffer (75 mmol/l Tris–HCl pH 6.8, 15% sodium dodecyl   sulfate, 5% 
β-mercaptoethanol, 2% glycerol, 0.001% bromophenol blue) using MagNa 
Lyser green beads in the MagNa Lyser. Samples (all ~60 μg protein) were 
boiled for 5 minutes, loaded on a 4–7% gradient polyacrylamide gel and 
run overnight at 4 °C. Gels were blotted to nitrocellulose BA83 (Whatman, 
Hertogenbosch, the Netherlands) for 6 hours at 4 °C. Blots were blocked 
with 5% nonfat dried milk (Campina, Rotterdam, the Netherlands) in 
PBS followed by an overnight incubation with NCL-DYS1 (dilution 1:125; 
NovaCastra, Newcastle, UK) in Tris-buffered saline plus 0.05% Tween-20 
to  detect  dystrophin.  The  fluorescent  IRDye  800CW  goat  anti-mouse 
immunoglobulin (dilution 1:5,000; Li-Cor, Lincoln, NE) was used as a 
  secondary antibody. Blots were visualized and quantified with the Odyssey 
system and software (Li-Cor).
Immunofluorescence analysis arrector pili muscle. Sections of skin biop-
sies taken from anterior leg, dorsal tail region, and neck scuff region of 
treated mdx, untreated mdx, and wild-type mice were labeled with anti-
dystrophin antibody (rabbit polyclonal; Santa Cruz Biotechnology, Milan, 
Italy) and incubated with a TRITC-conjugated secondary antibody (DAKO, 
Milan, Italy). All samples were double-labeled with an anti-desmin anti-
body (goat polyclonal 1:10; Santa Cruz Biotechnology) and incubated with 
anti-goat  fluorescein  isothiocyanate-conjugated  antibody  (1:100;  Sigma 
Aldrich). All samples were observed with a Nikon Eclipse 80i fluorescence 
microscope (Nikon Instruments, Florence, Italy).
CK analysis. Blood was collected in a minicollect tube (Greiner bio-one, 
Alphen aan de Rijn, the Netherlands) through a small cut at the end of the 
tail. Serum CK levels were determined using Reflotron CK strips (Roche 
Diagnostics) in the Reflotron Plus (Roche Diagnostics).
Rotarod analysis. Mice were placed on the Rotarod (Ugo Basile, Comerio, 
Italy), which accelerated from 5 to 45 r.p.m. in the first 15 seconds. The 
time spent on the rod was recorded. The session was ended when mice 
were able to run for 500 seconds. Mice that fell off within 500 seconds were 
given a maximum of two more tries. The longest running time was used 
for analyses.
Statistical analysis. Linear regression analyses were performed with the R 
package (http://www.Rpackage.org).
suPPleMentAry MAterIAl
Table S1.  Outline of the different experiments.
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